Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: The effect of gender, race, and CYP2B6 polymorphism

摘要: AIMS: To characterize the demographic and pharmacogenetic factors that influence interpatient variability in plasma concentrations of HIV non-nucleoside reverse transcriptase inhibitor efavirenz. METHODS: Data from all samples analyzed for efavirenz our TDM service 2002 2003 were reviewed. Information on gender, age, body weight, height, race, hormonal contraceptive use (in a subset patients), time between sampling last intake was recorded. PCR-restriction fragment length polymorphism analysis performed to detect cytochrome P450 2B6 (CYP2B6) C1459T variant (present CYP2B6*6 CYP2B6*7) which is associated with low CYP2B6 activity. RESULTS: A total 255 patients included this analysis. The median concentration 2.50 (interquartile range: 1.85-3.55) mg l(-1). Eight (3.1%) considered have subtherapeutic ( 4.0 l(-1)). Gender, after intake, race only significantly related multivariate No observed use, presence polymorphism. CONCLUSIONS: Gender are important determining unaffected by Physicians should be particularly alert signs efavirenz-induced toxicity females non-Caucasian patients.